To cite this paper use one of the standards below:
Lopinavir (LPV) is an antiretroviral drug used to control human immunodeficiency virus infection. Its low oral bioavailability, complex therapeutic regimen and adverse effects hampers therapy efficiency1. To do so, nanostructured lipid carriers containing LPV (CLN-LPV) were developed and drug electrical stability was verified prior to permeation studies. Lipid nanoparticles were composed with stearic acid, oleic acid, surfactants and different LPV content (0.5 to 1.5 mg/mL). Mean diameter increased with higher LPV content (p<0.05) (145.8 ± 5.2 to 179.0 ± 2.5 nm). Electrical stability of LPV (1mg/mL) was assessed and 92.4 ± 1.02% of drug recovery was achieved. Electrical stability of CLN-LPV demonstrated no drug degradation, but entrapment efficiency was decreased (to 87.03 ± 0.33% to 80.02 ± 0.79%). Iontophoresis significantly increased drug skin permeation compared to passive permeation (p<0.05). CLN-LPV combined with iontophoresis seems to be promising formulation for LPV transdermal delivery.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper